Common Shares, no par value
- Symbol
- BHVN
- Exchange
- NYSE
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Biohaven Ltd.
BHVNNYSEEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On May 4, 2026, Biohaven Ltd. (the “Registrant”) issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference. In accordance with General Instruction B.2.…
Company context
Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, obesity, neuroscience, and oncology. The Company is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and preclinical programs include Kv7 ion channel modulation for epilepsy; MoDE and TRAP extracellular protein degradation for immunological diseases; and myostatin inhibition for neuromuscular and metabolic diseases, including obesity.
Current securities
Registered securities in this filing
Biohaven Ltd. · 8-K · Filed 2026-05-04
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On May 4, 2026, Biohaven Ltd. (the “Registrant”) issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.
Filed exhibits (1)
EX-99.1 2 a2026q1bhvnearningsprex991.htm EX-99.1 Document Exhibit 99.1 Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results • Biohaven to update clinical, regulatory, and operational progress at annual R&D Day at the upcoming Yale Innovation Summit on May 27, 2026. • Advancement of high-value, late-stage priority programs: ◦ Pivotal epilepsy program with selective Kv7 ion channel activator, opakalim, with expected topline results in 2H 2026. ◦ Phase 2 obesity study with myostatin-activin pathway inhibitor, taldefgrobep alfa, completed enrollment and topline data expected in 2H 2026. ◦ TRAP™ and MoDE™ Degraders Advancing to Pivotal Trials ▪ Pivotal trials in both IgA nephropathy (IgAN) with Gd-IgA1 TRAP degrader, BHV-1400, and Graves’ disease with IgG MoDE degrader, BHV-1300, expected to initiate by mid-year. • Sustained progress across development pipeline: ◦ Enrollment in Phase 2 early Parkinson’s disease trial with brain-penetrant TYK2/JAK1 inhibitor, BHV-8000, continues to advance. ◦ Enrollment advances in advanced endometrial cancer expansion cohort with the next-generation TROP-2 directed ADC BHV-1510 in combination with Libtayo…
Open exhibit ↗